Optimal management of hepatocellular carcinoma: Challenges and opportunities

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 8, 2010, Pages 1336-1338

  Lin, Chih Lin ^a,b   Kao, Jia Horng ^c,d,e  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; EARLY CANCER; EDITORIAL; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR ABLATION; TUMOR VOLUME;

EID: 77954908354     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06373.x     Document Type: Editorial

References (26)

1. World Health Organization. The Global Burden of Disease. 2004 update. Cited 8 Feb 2010. Available from URL: http://www.who.int/healthinfo/global- burden-disease/GBD-report-2004update-full.pdf
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
3. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004 127 (Suppl S5 16.
4. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
5. El Serag HB. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 2002 35 (Suppl S72 8.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009 59 : 225 249.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 1917.
8. Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv. Ther. 2008 25 : 1089 1104.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003 37 : 429 442.
10. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008 359 : 378 390.
11. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet. Oncol. 2009 10 : 25 34.
12. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999 29 : 62 7.
13. Tseng PL, Wang JH, Tung HD et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J. Gastroenterol. Hepatol. 2010 25 1426 1434.
14. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005 25 : 696 703.
15. Kao JH, Chen DS. Hepatocellular carcinoma in Taiwan: progress in the past decade 1988-1997. In : Leong ASY, Liew CT, Lau JWY, Johnson PJ, eds. Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. 1999; 23550
16. Kao JH, Chen DS. Overview of hepatitis B and C viruses. In : Goedert JJ, ed. Infectious Causes of Cancer: Targets for Intervention. 2000; 31330
17. Lin CL, Chen JD, Liu CJ et al. Clinicopathological differences between hepatitis B viral genotype B and C-related resectable hepatocellular carcinoma. J. Viral. Hepat. 2007 14 : 64 9.
18. Lu SN, Wang JH, Liu SL et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006 107 : 2212 2222.
19. Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004 127 : S104 7.
20. Sato T, Tateishi R, Yoshida H et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol. Int. 2009 3 : 544 550.
21. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
22. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010 30 : 61 74.
23. Farinati F, Sergio A, Baldan A et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009 9 : 33 45.
24. Shah SA, Wei AC, Cleary SP et al. Prognosis and results after resection of very large (> or =10 cm) hepatocellular carcinoma. J. Gastrointest. Surg. 2007 11 : 589 595.
25. Makuuchi M, Kokudo N, Arii S et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol. Res. 2008 38 : 37 51.
26. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J. Gastroenterol. 2009 44 (Suppl 119 121.